MERZ-AESTHETICS
Merz Aesthetics, the world’s largest dedicated medical aesthetics business, is presenting new data for its product portfolio in addition to perspectives on medical aesthetics trends at the 2024 Aesthetic and Anti-Aging Medicine World Congress. AMWC is a leading global scientific conference specializing in aesthetic and anti-aging medicine. Participants can attend live in Monaco or tune in virtually beginning March 27 through March 29, 2024.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240321775430/en/
Merz Aesthetics’ programming includes a sponsored symposium on March 28 from 14:00 - 16:00 CET, Beauty Without Borders: Aesthetics Across Continents, moderated by Dr. Sabrina Fabi, featuring commentary from Dr. Kate Goldie, Dr. Siew Tuck Wah, Dr. Rolf Bartsch and Dr. Rossana Vasconcelos. During the session, the group will discuss the multifaceted landscape of beauty and aging around the world, the nuances and variances of aging concerns among different patient populations and the recommended techniques and products.
“Each year, AMWC allows us the opportunity to connect and collaborate with peers from around the world and provides a forum to showcase our research and advancements in medical aesthetics,” said Terri Phillips, MD, Chief Medical Affairs Officer, Merz Aesthetics. “We’re excited to engage in scientific exchange, foster new connections and discuss innovations within our portfolio, in addition to sharing insights from the evolving field of regenerative aesthetics.”
“At Merz Aesthetics, we aim to provide the best experience possible for our health care professionals and their patients,” said Gonzalo Mibelli, President, EMEA, Merz Aesthetics. “I’m looking forward to presenting our latest data and honoring the commitment we’ve made to our customers to meet their evolving needs.”
In addition to the symposium, Merz Aesthetics is presenting five e-posters for the first time. The abstracts will be available for viewing on-site throughout the congress and displayed on the virtual e-poster platform with detailed abstracts. Following are the highlighted e-posters:
- Long-term Duration and Safety of CaHA(+)-CMC for the Treatment of Jawline – Jeremy B. Green, MD, Roberta Del Campo, MD, Alan J. Durkin, MD, David K. Funt, MD, Nicole Nasrallah, MS, Keith Martinez, PhD, Amir Moradi, MD
- Tissue Integration of Hyaluronic Acid-Containing Dermal Fillers: Automated Approach Using a Human Skin Model Under Optimal Tension – Kay Marquardt, PhD, Christian Hartmann, PhD, Michael Conneely, PhD, Robyn Hickerson, PhD, Kristina Riegel, PhD, Thomas Hengl, PhD
- Stimulation of Elastin Neogenesis by Micro-Focused Ultrasound (MFU-V) – Kay Marquardt, PhD, Christian Hartmann, PhD, Flora Wegener, PhD, Nils Warfving, PhD, Kristina Riegel, PhD, Thomas Hengl, PhD
- Consensus Agreements on Regenerative Aesthetics: Terminology, Goals, and Strategies – Dr. Kate Goldie, Dr. Greg Chernoff, Dr. Niamh Corduff, Dr. Owen Davies, Dr. Jani van Loghem, Dr. Bianca Viscomi
- Micro-focused Ultrasound with Visualization and Aesthetic Outcomes: A Systematic Review and Meta-analysis of Clinical Studies – Dr. Sabrina Guillen Fabi, Dr. Gabriela Casabona, Dr. Tatjana Pavicic, Dr. Julia Sevi, Dr. Julieta Spada, Dr. Vasanop Vachiramon, Dr. Rossana Vasconcelos, Dr. Siew Tuck Wah
Merz Aesthetics will be located at Booth J1 on Level 1.
About Merz Aesthetics
Merz Aesthetics is a medical aesthetics business with a long history of empowering health care professionals, patients and employees to live every day with confidence. We aim to help people around the world look, feel and live like the best versions of themselves — however they define it. Clinically proven, its product portfolio includes injectables, devices and skin care treatments designed to meet each patient’s needs with high standards of safety and efficacy. Being family owned for more than 115 years, Merz Aesthetics is known for building unique connections with customers who feel like family. Merz Aesthetics’ global headquarters is in Raleigh, N.C., USA, with a commercial presence in 90 countries worldwide. It is also a part of Merz Group, which was founded in 1908 and is based in Frankfurt, Germany. Learn more at merzaesthetics.com.
Copyright © 2024 Merz Aesthetics GmbH. All rights reserved. MERZ, MERZ AESTHETICS and the MERZ logo are registered trademarks of Merz Pharma GmbH & Co. KGaA.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240321775430/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
New Study Reveals Surging Consumer Demand for Seamless Car-to-Home Audio10.12.2025 08:10:00 CET | Press release
Cinemo and Futuresource Consulting’s research indicates consumer readiness for integrated audio environments, accelerating the shift from connected devices to a connected lifestyle. Over 9 in 10 consumers say they are likely to seek out audio devices that allow smooth movement between car and home, according to a consumer survey conducted by Futuresource Consulting on behalf of Cinemo, a leading provider of in-car infotainment solutions and the company behind the first open cloud ecosystem connecting audio devices, content, and users. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251209006640/en/ "From Living Room to Driver’s Seat: Exploring the Demands of a Unified Audio Experience" Survey conducted by Futuresource Consulting on behalf of Cinemo; November 2025 The report, “From Living Room to Driver’s Seat: Exploring the Demands of a Unified Audio Experience”, drawn from more than 500 connected device users in China, where
Polpharma Biologics and Libbs Farmacêutica Sign Licensing Agreement for a Biosimilar for Autoimmune Diseases10.12.2025 07:01:00 CET | Press release
Polpharma Biologics, a leading biopharmaceutical company specializing in the development and manufacturing of biosimilars, is thrilled to announce the signing of a landmark licensing agreement with the Brazilian company Libbs Farmacêutica! Through this strategic partnership, Libbs Farmacêutica will gain exclusive rights to commercialize a cutting-edge biosimilar for autoimmune diseases in the rapidly growing Brazilian market. Polpharma Biologics retains full responsibility for the development and manufacturing of the biosimilar. Libbs Farmacêutica will hold an exclusive license for the commercialization, marketing and distribution of the biosimilar in Brazil. This collaboration opens up exciting new opportunities and demonstrates the shared commitment of both companies to delivering innovative and accessible therapies to patients. “Entering the Brazilian market with a biosimilar is a significant step for Polpharma Biologics and reflects our ongoing mission to expand access to high-qual
NayaPay Launches Global QR Payments for Pakistanis via Alipay+10.12.2025 05:00:00 CET | Press release
NayaPay, one of Pakistan’s fastest growing fintech platforms, has launched global QR payments in collaboration with Alipay+, Ant International’s global wallet gateway. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251209591389/en/ The partnership enables millions of NayaPay users to scan-and-pay at Alipay+ merchants initially across more than 50 countries, connecting Pakistani consumers to an extensive global ecosystem spanning retail, dining, transport, healthcare, entertainment and more. With this innovative feature, paying abroad just got faster and more affordable. With NayaPay, Pakistanis can now scan and pay securely worldwide with lower costs, less friction, and a seamless checkout experience wherever they go. Alipay+ connects 40 international mobile payment partners to more than 150 million merchants globally. The launch reinforces NayaPay’s commitment to delivering world-class payment experiences to Pakistani consu
Biocytogen Completes STAR Market IPO, Becoming the First “H+A” Global Drug Innovator10.12.2025 03:50:00 CET | Press release
Biocytogen (Beijing) Pharmaceutical Technology Co., Ltd. (“Biocytogen,” SSE: 688796; HKEX: 02315), a global biotechnology company advancing innovative drug discovery, today announced its successful listing on the Shanghai Stock Exchange STAR Market. This follows the Company’s listing on the Hong Kong Stock Exchange in September 2022 and marks a significant milestone in establishing Biocytogen as the first “H+A” dual-listed global drug innovator, reinforcing its mission to become the global headstream of new drugs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251209977992/en/ The Company’s IPO price was set at 26.68 RMB per share, with an opening price of 58 RMB, representing a 117% increase over the offering price. Based on the opening price, Biocytogen’s market capitalization exceeds 25.9 billion RMB. Biocytogen’s proprietary RenMice® platforms (RenMab™, RenLite®, RenNano®, RenTCR-mimic™) enable the discovery of fully hum
Argo Infrastructure Partners Increases Ownership and Capital Commitment to TierPoint9.12.2025 23:00:00 CET | Press release
The latest investment brings total capital formation under Argo ownership to $3 billionDemonstrates a growing commitment to TierPoint from existing and new capital partners of Argo supporting the continued growth of its leading data center platform Argo Infrastructure Partners, LP (“Argo”), an established mid-market asset manager of essential infrastructure assets in North America, today announced it has acquired on behalf of its managed funds the equity interests of the majority of minority shareholders in TierPoint. The transaction reflects Argo’s continued conviction in TierPoint’s strategy and growth potential during a period of accelerating demand for TierPoint’s enterprise-class data center services. Since Argo’s initial investment in 2020, $3 billion of capital has been raised to fund growth and reduce TierPoint’s cost of capital by terming out debt facilities. The investment capital has advanced TierPoint’s market position as a data center services provider to enterprises, gove
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom